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Introduction
Tuberculosis is a common notifiable infectious disease in Hong Kong; 5348 cases were 
notified in 2009.1 Mycobacterium tuberculosis (MTB) is known as the ‘great mimicker’ 
and has a diverse range of clinical presentations. One of its rare but fatal manifestations 
is secondary haemophagocytic lymphohistiocytosis (HLH), which has a mortality rate of 
100% in the absence of anti-tuberculous treatment.2 Failure to consider tuberculosis in 
secondary HLH leads to delayed initiation of appropriate treatment and poor outcomes. 
This report describes two patients with tuberculosis-associated HLH and reviews 55 other 
local and international cases reported in the literature.
Case reports
Case 1
A 78-year-old Chinese woman was admitted to hospital with a 1-week history of 
severe anorexia, fever, and left hip pain. Three months earlier, she had sustained a left 
intertrochanteric fracture after a non-syncopal fall, for which she had a dynamic hip screw 
insertion. She did not smoke or drink, and had well-controlled hypertension whilst taking 
amlodipine 5 mg daily. She had no personal or contact history of tuberculosis. Physical 
examination revealed that she was cachexic and dehydrated, with a temperature of 36.5°C, 
blood pressure of 165/98 mm Hg, heart rate of 91 beats/min, and a body weight of 53 kg. 
Muscle power was reduced to grade 4/5 in the left lower limb and left hip movement was 
limited by pain. The healed wound over the left hip looked unremarkable. 
 After admission, the patient was noted to have persistent fever despite broad-spectrum 
antibiotic cover including β-lactams (sequential use of intravenous amoxicillin/clavulanate, 
ceftriaxone, ceftazidime and meropenem), oral azithromycin, and oral doxycycline. 
Significant blood test abnormalities included: pancytopaenia, hypoalbuminaemia, deranged 
liver function, hypertriglyceridaemia, hyperferritinaemia, raised lactate dehydrogenase, C-
reactive protein level, and erythrocyte sedimentation rate levels. She had a coagulopathy 
that included hypofibrinogenaemia and a raised D-Dimer level (Table 1). Clotting factor 
assays suggested vitamin K deficiency, whilst tests for the lupus anticoagulant and anti-
cardiolipin antibody were negative, as was the factor inhibitor screen. She underwent 
bone marrow aspiration and biopsy, which revealed increased reactivity of histiocytes 
showing haemophagocytic activity (Fig 1a). Given the constellation of fever, pancytopaenia, 
hypertriglyceridaemia, hyperferritinaemia, hypofibrinogenaemia, and haemophagocytosis 
in bone marrow, a diagnosis of HLH was established.
 She underwent extensive workup to elucidate the underlying cause of the HLH. 
The tumour markers and autoimmune markers were normal, making the possibility of 
malignancy and autoimmune disease unlikely. Serial chest radiographs showed gradual 
deterioration with the appearance of miliary shadows suggesting infection, particularly 
tuberculosis as the primary abnormality. Empirical anti-tuberculous treatment (isoniazid, 
rifampicin, ethambutol and pyrazinamide) was commenced. Subsequently, gallium scan 
showed intense focal uptake at the left sub-trochanteric region, mild left chest infection, 
and right hilar lymphadenopathy. Contrast computed tomography of the brain, thorax, 
abdomen, pelvis, and the left hip revealed the presence of diffuse miliary nodules in both 
lung fields (Fig 1b). There was a small abscess measuring 1.2 cm in diameter in the right 
psoas muscle and another measuring 4.7 cm x 3.9 cm x 8 cm over the lateral side of the 
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Secondary haemophagocytic lymphohistiocytosis is a rare but fatal complication of 
tuberculosis. We describe two cases, and review the local and international experience on 
the management of this clinical entity. Prompt treatment with anti-tuberculous drugs forms 
the cornerstone of therapeutic success.
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繼發性噬血症候群是一種罕見但可致命的肺結核病的併發症。本文報
告兩個有關病例，並討論本地及外國對於這種病的治療方法。及時使
用抗結核藥物是成功治療噬血症候群的基石。
噬血症候群：一種罕見肺結核病的臨床表現
left hip. Ultrasound-guided drainage of the abscess 
yielded a few millilitres of blood-stained fluid. Gram 
stain of the smear as well as aerobic and anaerobic 
culture of the fluid were negative, as were tests for 
MTB by polymerase chain reaction (PCR), smear and 
culture for acid-fast bacilli (AFB). A lytic lesion in the 
left side of the fifth lumbar vertebrae was noted. 
Subsequently, culture of the blood, sputum, early 
morning urine, and bronchoalveolar lavage all yielded 
MTB, although the initial smears were all negative. The 
overall diagnosis was HLH secondary to disseminated 
tuberculosis. The patient’s clinical status, biochemical 
parameters, and radiological abnormalities gradually 
improved after commencement of anti-tuberculous 
treatment, which was continued for 18 months. She 
remained well at follow-up 5 months after completion 
of the treatment.
Case 2
An 80-year-old Chinese man presented with severe 
anorexia and fever for 3 months. He was a chronic 
smoker, had a history of paroxysmal atrial fibrillation, 
and was taking aspirin. He had no personal or contact 
history of tuberculosis. On physical examination, 
the patient was cachexic and dehydrated. He 
had a blood pressure of 93/62 mm Hg, pulse rate 
of 63 beats/min, and temperature of 35.9°C. Left 
cervical lymphadenopathy was detected. Significant 
blood test abnormalities included pancytopaenia, 
hypoalbuminaemia, elevated levels of alkaline 
phosphatase, ferritin, lactate dehydrogenase and 
C-reactive protein. He had a coagulopathy with a 
prolonged activated partial thromboplastin time, as 
well as borderline fibrinogen, and raised D-Dimer 
levels (Table 1). His bone marrow aspirate revealed 
markedly increased reactive histiocytes and 
prominent haemophagocytic figures. His trephine 
biopsy showed prominent granulomatous inflamma-
tion comprising epithelioid histiocytes and Langhans 
FIG 1.  Case 1: (a) Bone marrow smear showing ingestion of 
erythrocytes and platelets by activated macrophages (Wright 
Giemsa stain, x 100 oil immersion). (b) High-resolution 
computed tomography of the lungs showing numerous tiny 
nodules distributed diffusely in both lungs with a small right-
sided pleural effusion and basal atelectasis
(a)
(b)
TABLE 1.  Blood test abnormalities of cases 1 and 2
Blood test Level Reference 
range
Case 1 Case 2
Total white cell count (x 109 /L) 1.70 1.77 4.4-10.10
Haemoglobin (g/L) 86 88 124-168
Platelet count (x 109 /L) 37 29 170-380
Albumin (g/L) 15 18 39-50
Alkaline phosphatase (U/L) 321 190 42-110
γ-Glutamyltransferase (U/L) 216 - 11-62
Aspartate aminotransferase (U/L) 131 - 15-38
Triglyceride (mmol/L) 2.8 - <1.7
Ferritin (pmol/L) >33 000 1530 52-738
Lactate dehydrogenase (U/L) 751 291 118-221
C-reactive protein (nmol/L) 1057 706 <72.4
Erythrocyte sedimentation rate (mm/h) 96 - 0-20
International normalised ratio 2.0 1.3 -
Activated partial thromboplastin time (s) 58 50 25.9-33.7
Thrombin time (s) 37 - 11-15
Fibrinogen (µmol/L) 1.18 3.38 4.29-9.94
D-Dimer level (nmol/L) 11-44 3-11 <3
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giant cells, and Ziehl-Neelsen staining showed many 
AFB. Given the constellation of fever, pancytopaenia, 
hyperferritinaemia, borderline fibrinogen and 
haemophagocytosis in bone marrow, a diagnosis of 
tuberculosis-related HLH was entertained.
 Further workup included tests for tumour 
autoimmune markers, vitamin B12, folate, thyroid 
stimulating hormone, cortisol, and serum and 
urine protein electrophoresis, all of which yielded 
no abnormality. Chest X-ray did not show any 
consolidation. Positron emission tomography and 
computed tomography showed multiple segments 
of large bowel with thickening and hypermetabolism, 
mostly affecting the ascending colon (Fig 2). In 
addition, there were multiple hypermetabolic lymph 
nodes in the cervical region and mediastinum, and 
bilateral pleural effusions with partial collapse of 
both lower lobes. Early morning gastric aspirate and 
urine culture yielded MTB. Despite treatment with 
supportive blood product transfusion, and anti-
tuberculous therapy comprising isoniazid, rifampicin, 
ethambutol and pyrazinamide, the patient’s condition 
deteriorated progressively and he succumbed 1 
month later.
Literature review
On 6 October 2011, we searched PubMed using 
the terms “tuberculosis”, “hemophagocytic”, 
“hemophagocytosis”, and “lymphohistiocytosis”. 
A total of 55 cases, three local (Table 23-5) and 52 
international (Table 36-47), of tuberculosis-associated 
HLH were found.
Local cases
Including our patients, there were five locally 
reported cases of tuberculosis-associated HLH. Their 
mean age was 61 (range, 36 to 80) years; three were 
female and two male (Table 2). The most common 
clinical features were fever (80%), and pancytopaenia 
(80%) or bicytopaenia (in the remaining 20%). One 
of these five patients had splenomegaly, three had 
pre-existing conditions (nasopharyngeal carcinoma, 
sarcoidosis, and systemic lupus erythematosus) for 
which they received corticosteroids. Four of these 
patients received anti-tuberculous treatment, three 
of whom died (our case 1 being the exception), which 
gives an overall mortality of 80%.
International cases
The clinical details were available for 48 of the 55 
reported cases (Table 3). Of the 45 patients in which 
the gender was reported, their mean age was 47 years 
(range, 14 days to 83 years), and 26 (58%) were male 
FIG 2.  Positron emission tomography scan showing 
hypermetabolism and wall thickening at the ascending colon in 
case 2
TABLE 2.  Local cases of tuberculosis-associated haemophagocytic lymphohistiocytosis
Patient No. 
[reference]
Gender/
age 
(years)
Site(s) of isolation of 
Mycobacterium tuberculosis
Co-morbidities Fever Hepatomegaly / 
splenomegaly
Platelet 
count (x 
109 /L)
Immuno- 
therapy 
(form of 
therapy)
Anti-
tuberculous 
treatment
Outcome
1 [3] F/69 Lungs, cervical lymph nodes Nasophageal 
carcinoma
Yes No 70 No No Death
2 [4] M/42 Lungs, kidneys, liver, spleen, 
prostate
Sarcoidosis Yes Splenomegaly 96 Yes 
(steroids)
Yes Death
3 [5] F/36 Blood, bone marrow Systemic lupus 
erythematosus
Yes No 92 Yes 
(steroids)
Yes Death
4 (case 1) F/78 Lung, L5 vertebrae, left 
greater trochanter collection, 
peripheral blood
Hypertension Yes No 37 No Yes Recovery
5 (case 2) M/80 Lung, lymph node, bowel, 
urinary system, bone marrow
Paroxysmal 
atrial fibrillation
No No 29 No Yes Death
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TABLE 3.  International cases of tuberculosis-associated haemophagocytic lymphohistiocytosis (HLH)*
Patient 
No. 
[reference]
Gender/
age 
(years)
Site(s) of isolation 
of Mycobacterium 
tuberculosis
Co-morbidities Fever Hepato-
megaly / 
splenomegaly
Platelet 
count (x 
109 /L)
Immunotherapy 
(form of therapy)
Anti-
tuberculous 
treatment
Outcome
6 [6] M/50 Adrenal glands N/A Yes Yes 142 Yes (steroid) Yes Death
7 [7] M/70 Liver, spleen, kidney, bone 
marrow, nodes from azygo-
esophageal angle
N/A Yes Yes 130 Yes† Yes Death
8 [8] M/43 Hilar lymph nodes, liver, 
bone marrow
N/A Yes Splenomegaly 157 Yes† Yes Recovery
9 [9] M/76 Liver, spleen, 
lymphadenopathy, pancreas, 
kidneys, lungs, adrenal 
glands, vertebra
Small cell carcinoma Yes Hepatomegaly Low No No Death
10 [9] F/68 Liver, spleen, lymph 
nodes, pancreas, lungs, 
kidneys, adrenal glands, 
endometrium, myometrium, 
large bowel
N/A Yes No 64 No No Death
11 [9] M/59 Liver, spleen, 
lymphadenopathy, pancreas, 
lungs, kidneys, adrenal 
glands, mediastinal lymph 
nodes
Diabetes mellitus Yes No Normal No No Death
12 [10] F/14 Lungs, bone marrow N/A Yes Yes 113 Yes 
(epipodophyllotoxin)
Yes Recovery
13 [11] M/83 Lymph nodes, sputum, urine N/A Yes No 120 No Yes Recovery
14 [11] M/70 Mediastinal lymph nodes, 
spleen
N/A Yes No 37 Yes† Yes Recovery
15 [12] M/38 Lungs, bone marrow N/A Yes Yes 20 Yes (splenectomy) Yes Recovery
16 [13] M/37 Bone marrow Renal transplant on 
haemodialysis
Yes Yes 15 No No Death
17 [14] M/43 Lungs AIDS Yes No 19 No Yes Death
18 [15] M/40 Cervical lymph node N/A Yes Yes 55 No Yes Recovery
19 [16] F/73 Bone marrow End-stage renal 
disease on 
haemodialysis
Yes Yes 146 No Yes Recovery
20 [17] M/22 Lymph nodes (HLH 
developed after anti-TB Rx)
N/A Yes Yes 10 No Yes Recovery
21 [18] F/53 Blood AIDS Yes Hepatomegaly 163 Yes (methyl-
prednisolone, IVIG, 
and lenograstim)
Yes Death
22 [19] F/14 
days
Blood, gastric, lungs N/A Yes Yes 58 Yes (hydrocortisone) Yes Recovery
23 [20] F/56 Lungs Myelodysplastic 
syndrome, chronic 
glomerulonephritis on 
haemodialysis
Yes Yes 45 Yes (steroid and 
plasma exchange)
Yes Recovery
24 [21] F/31 Lungs, bone marrow, cervical 
lymph nodes
Stage IV high-grade 
Hodgkin’s lymphoma
Yes Splenomegaly Low Yes (fludarabine, 
chlorambucil, and 
prednisone)
Yes Recovery
25 [22] M/40 Lungs Renal dysfunction on 
haemodialysis
Yes No 81 Yes (steroid and 
plasma exchange)
Yes Recovery
26 [23] F/9 Lungs, bone marrow, liver, 
spleen, central nervous 
system
N/A Yes Yes 47 Yes (prednisone) Yes Recovery
27 [24] M/67 Liver, spleen, lungs, celiac 
lymph nodes, granuloma
Claudication; status 
post aorta-iliac 
bypass
Yes Yes 150 No No Death
28 [25] N/A / 44 N/A Renal transplant, 
nephroangiosclerosis, 
haemodialysis
Yes Yes 8 Yes (steroid and 
antithymocyte 
globulins)
Yes Death
29 [25] N/A / 45 N/A B lymphoma, 
membranous 
nephropathy, 
renal transplant, 
haemodialysis
Yes Yes 129 No Yes Recovery
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TABLE 3.  (Cont'd)
Patient 
No. 
[reference]
Gender/
age 
(years)
Site(s) of isolation 
of Mycobacterium 
tuberculosis
Co-morbidities Fever Hepato-
megaly / 
splenomegaly
Platelet 
count (x 
109 /L)
Immunotherapy 
(form of therapy)
Anti-
tuberculous 
treatment
Outcome
30 [26] F/7 
weeks
Lungs N/A Yes Yes 125 No No Death
31 [27] F/60 Lungs N/A Yes Hepatomegaly - No Yes Recovery
32 [28] M/75 Lungs, bone marrow Chronic renal failure 
on haemodialysis
Yes No 121 Yes (IVIG) Yes Death
33 [29] F/29 Lung N/A Yes Yes 437 No Yes Recovery
34 [30] F/83 Bone marrow Chronic renal failure 
on haemodialysis, 
hypertension
Yes Splenomegaly 37 No No Death
35 [31] M/52 Lungs N/A Yes No 268 No Yes Recovery
36 [32] M/40 Lungs, stomach Candidial 
oesophagitis
Yes Yes 30 Yes (methyl-
prednisolone, and 
IVIG)
Yes Recovery
37 [32] M/46 Ileum N/A Yes Yes 303 No Yes Recovery
38 [33] M/15 Bone marrow, liver, 
spleen, lymph nodes
N/A Yes Hepatomegaly 65 Yes (IVIG) Yes Recovery
39 [34] M/28 Liver, small bowel, colon Schistosomiasis Yes Splenomegaly 118 Yes (dexamethasone) Yes Death
40 [35] M/63 Lung, bone marrow Diabetes mellitus Yes Yes 78 Yes (etoposide) Yes Death
41 [36] M/41 Mediastinal and hilar 
lymph nodes
Wegener’s 
granulomatosis 
(received 3 infusions 
of infliximab for 
scleritis and uveitis)
Yes Yes 196 Yes (vincristine) Yes Recovery
42 [37] M/17 Lymph nodes, bone 
marrow
N/A Yes Yes 70 Yes (dexamethasone) Yes Recovery
43 [38] N/A / 30 Lungs, pleura, mediastinal 
lymph nodes
N/A Yes N/A Low Yes (steroid) Yes Recovery
44 [39] M/52 
days
Lungs, liver, lymph nodes Seborrhoeic 
dermatitis
Yes Yes 75 Yes (IVIG) Yes Death
45 [40] F/48 Lungs, bone marrow Crohn’s disease 
(received infliximab)
Yes Yes Low Yes (steroid and 
IVIG)
Yes Recovery
46 [41] F/70 Multiple organs Acute renal failure 
due to crescentic 
glomerulonephritis 
on haemodialysis
Yes N/A Low Yes (chemotherapy, 
and steroid)
Yes Death
47 [42] M/68 Bone marrow N/A Yes Yes 25 Yes (prednisolone) Yes Recovery
48 [42] F/67 Lungs, bone marrow N/A Yes No 114 Yes (methyl-
prednisolone)
Yes Death
49 [43] F/76 Lungs, bone marrow N/A Yes No Low Yes (steroid) Yes Recovery
50 [44] F/59 Lungs N/A Yes N/A Low Yes (steroid) Yes Death
51 [45] M/48 Lungs, urine, bone 
marrow
N/A Yes N/A Low Yes 
(methylprednisolone, 
etoposide)
Yes Recovery
52 [46] F/63 Bone marrow, lungs, liver, 
spleen, kidney
Aplastic anaemia Yes N/A Low Yes (methyl-
prednisolone)
No Death
53 [47] F/56 Bone marrow Diabetes mellitus 
complicated with 
nephropathy
Yes N/A Low No No Death
* AIDS denotes acquired immunodeficiency syndrome, anti-TB Rx anti-tuberculous treatment, IVIG intravenous immunoglobulin, and N/A not available
† Form of immunotherapy was not described
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and 19 (42%) were female. Among them, 42% had 
underlying co-morbidities; eight had chronic renal 
failure, four had malignancy, three had diabetes 
mellitus, two had acquired immunodeficiency 
syndrome (AIDS), two were in receipt of infliximab 
for Crohn’s disease and Wegener’s granulomatosis, 
and one had aplastic anaemia. All 48 patients had 
fever, and 47 (98%) had thrombocytopaenia. Of 
the 42 cases in which the presence or absence of 
hepatosplenomegaly was reported, 32 (76%) had such 
organomegaly. Overall mortality in these 48 patients 
was 44%. All nine patients who did not receive anti-
tuberculous treatment died. Among patients who 
received anti-tuberculous treatment with or without 
immunotherapy, the survival rate was 68% (27/40), the 
highest rate (9/10) being in those who did not receive 
immunotherapy. The immunotherapies reported 
to have been given included high-dose steroids, 
intravenous immunoglobulin, chemotherapy (eg 
etoposide or vincristine), splenectomy, plasma 
exchange, and epipodophyllotoxin.
Discussion
Being a disorder of the macrophage lineage, HLH is 
characterised by the finding of haemophagocytosis 
(ie activated macrophages engulfing erythrocytes, 
leukocytes, platelets, and their precursor cells). The 
disorder is classified into primary and secondary 
forms. Primary or familial HLH belongs to a group of 
genetic diseases with impaired immune cell function 
(cytotoxic T and natural killer [NK] cells) that affects 
children, usually before the age of 2 years. Secondary 
HLH may occur at any age and is usually caused by 
infections, autoimmune diseases, malignancies, or 
drugs2,42 (Table 4). The diagnosis of HLH is deemed 
to be made when at least five of the following eight 
criteria are fulfilled2:
(a) Splenomegaly
(b) Fever (>7 days)
(c) Bicytopaenia without marrow hypoplasia 
including haemoglobin <90 g/L, platelet count 
<100 x 109 /L, neutrophil count <1.10 x 109 /L
(d) Fasting hypertriglyceridaemia (>3.0 mmol/L) 
and/or hypofibrinogenaemia (<1.5 g/L)
(e) Hyperferritinaemia (>500 μg/L; 1125 pmol/L)
(f) Low or absent NK cell activity
(g) Increased soluble CD25 levels (>2400 IU/mL)
(h) Histologically evident haemophagocytosis
 Tuberculosis is an uncommon but important 
cause of secondary HLH, accounting for about 
3% of all cases, and affects all age-groups.2 Failure 
to establish the diagnosis of HLH secondary to 
tuberculosis inevitably leads to an adverse outcome. 
While patients may have clinically overt symptoms 
and signs suggestive of tuberculosis, occasionally 
the manifestations may be subtle or atypical. 
Among the local cases, 4/5 (80%) did not have any 
respiratory symptom in the initial stage (patients 1, 
3, 4, and 5). Furthermore, unlike the international 
cases, hepatosplenomegaly was rare (20% vs 76%). 
As tuberculosis is endemic in our region, this 
treatable cause should be actively sought in all our 
patients with HLH. This entails collecting specimens, 
including sputum, early morning gastric aspirates, 
early morning urine, peripheral blood, and even body 
tissues (eg bone marrow and lymph node aspirates) 
for PCR, as well as microscopy and culture for AFB. 
Although mycobacteraemia is rare (8%) in human 
immunodeficiency virus (HIV)–negative patients with 
active tuberculosis, blood cultures for mycobacteria 
should be performed in clinically suspicious cases, 
as they may provide the first clue to underlying 
tuberculosis, as in patients 3 and 4 who had a 
peripheral blood smear positive for AFB and a blood 
culture positive for MTB, respectively. There were 
also two more patients with positive blood cultures 
for MTB among the international cases.18 Culture of 
the bone marrow appears to be a more sensitive test 
than peripheral blood cultures (38% vs 8%) to make 
the diagnosis.48 Prior to obtaining blood cultures for 
AFB, the microbiology laboratory should be alerted 
TABLE. 4  Aetiologies of secondary haemophagocytic lymphohistiocytosis (adopted from Claessens et al42)
Infection* Immune disorders Drugs Neoplasms Inflammatory diseases
Virus: herpes virus group, 
parvovirus B19, myxovirus, para-
influenza virus, HIV, hepatitis, 
enterovirus, morbillivirus
Duncan's disease (Purtilo 
syndrome), Chédiak-
Higashi syndrome, 
asplenia, cytotoxic drugs
Phenytoin, 
carbamazepine, 
minocycline, 
phenobarbital
Malignant lymphoma 
(especially T 
cell lymphoma, 
angioimmunoblastic 
lymphadenopathy)
Systemic lupus erythematosus, 
Still’s disease, rheumatoid arthritis, 
scleroderma, sarcoidosis, Kikuchi 
syndrome, Crohn’s disease, 
histiocytic cytophagic panniculitis
Bacteria: Brucella, mycobacteria, 
salmonella, mycoplasma, ehrlichia, 
rickettsia, borrelia, common 
bacteria
Hodgkin’s lymphoma, 
tricholeukocyte leukaemia, 
myelodysplastic syndrome, 
solid neoplasm
Parasites: anguillulose babesia, 
leishmania, plasmodium, 
toxoplasma
Fungus: candida, histoplasma, 
aspergillus, cryptococcus
* HIV denotes human immunodeficiency virus
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of the possibility, in order to use selective broths and 
culture methods to enhance the diagnostic yield.
 Though the exact pathogenesis of tuberculosis-
associated HLH is not clearly known, it is likely the 
phenomenon is related to immune dysregulation. 
Tuberculosis normally induces a Th1 response, in 
which cytotoxic Th1 cells and macrophages cooperate 
to increase the efficiency of cytotoxic lymphocytes 
and the capacity of macrophages to proliferate.2 
In secondary HLH, defective cytotoxic T cells and 
NK cells produce a disordered and inadequately 
regulated immune response that may result in the 
survival and proliferation of bacteria with ongoing 
immunological stimulation. Furthermore, the NK 
cells may be unable to regulate the immune response 
by effectively destroying the proliferating immune 
cells. The result could be a cytokine storm with 
uncontrolled macrophage proliferation manifesting 
as a variety of clinical and laboratory abnormalities.34 
Fever and tissue wasting are mainly caused by 
tumour necrosis factor-α (TNF-α).6 Cytopaenia results 
from haemophagocytosis in the bone marrow and 
depression of haematopoiesis by inhibitory cytokines 
such as interferon-γ (IFN-γ), TNF-α and interleukin-1β 
(IL-1β). Haemolysis leads to hyperbilirubinaemia and 
elevation of lactate dehydrogenase. Serum ferritin 
elevation is due to IL-1β elevation. 
 Hypertriglyceridaemia is due to lipoprotein 
lipase inhibition by TNF-α, whilst IFN-γ contributes to 
the development of cholestasis. Colony-stimulating 
factor together with Fas/Fas-ligand interaction in 
response to IFN-γ overproduction may contribute 
to apoptosis and liver damage. Elevation of IFN-γ 
levels leads to hypoalbuminaemia. Renal failure 
results from abnormally high concentrations of 
nephrotoxic IL-6. Other non-specific but possible 
laboratory abnormalities include hypo- or hyper-
gammaglobulinaemia, a positive Coomb’s test, 
and hyponatremia due to the syndrome of 
inappropriate anti-diuretic hormone secretion.2 
Coagulopathy may be related to thrombocytopaenia, 
hypofibrinogenaemia, or disseminated intravascular 
coagulation.2 Hypofibrinogenaemia is caused by 
activated macrophages, which can activate factor X 
of the coagulation cascade through Mac-1 receptors 
and activate the common pathway.49 Ooe49 also 
demonstrated that in autopsies of patients with familial 
HLH, fibrinogen antigens could be detected in the 
cytoplasm of approximately 10% of splenic histiocytes 
showing a diffuse staining pattern, indicating uptake 
of fibrin and/or fibrinogen molecules by these cells.
 There is a risk of developing tuberculosis-
associated HLH in the elderly population, in whom 
immunosenescence may be an important contributing 
factor. There were 16 cases of tuberculosis-associated 
HLH reported in patients aged >65 years; eight 
were male and eight were female, and six (38%) had 
underlying comorbidities (2 had malignancies and 
4 had underlying renal impairment). Immunosene-
scence is a multifactorial condition and consists 
of various age-related changes, including thymic 
involution, reduction of naïve T cells, decreased 
antigen responsiveness and proliferation.50,51 The NK 
cells are also less readily activated by IFN-α and have 
reduced cytotoxic activity, possibly by an intracellular 
decrease in calcium mobilisation.51 The increased 
production of prostaglandin E2 by aged activated 
macrophages may decrease T cell activation.51 Aged 
macrophages also generate reduced amounts of 
nitric oxide and superoxide and have diminished Toll-
like receptor expression and function.51
 Tuberculosis-associated HLH confers a high 
overall mortality (80% among local cases, and 44% 
among international cases), which was mainly due 
to under-recognition of the condition and delayed 
institution of treatment. As evident in our case 1, 
negative smear results in early investigations did not 
exclude the diagnosis. Empirical anti-tuberculous 
treatment should be considered if there is a high 
degree of clinical suspicion, such as persistent fever 
despite broad-spectrum antibiotic treatment, and 
interval radiological deterioration. First-line anti-
tuberculous drugs, including isoniazid, rifampicin, 
pyrazinamide, and ethambutol, can be appropriate. 
We were only able to trace the duration of treatment in 
two of the 27 successfully treated cases; one received 
9 months of therapy31 and the other 12 months.19 The 
World Health Organization guideline recommends 
treatment durations beyond 6 months in disseminated 
or extrapulmonary infections. The exact duration 
should be decided on a case-by-case basis.52
 Besides anti-tuberculous medications, other 
therapeutic options may serve as useful adjuncts in 
tuberculosis-associated HLH. They include various 
immunotherapies, among which glucocorticoids 
are the most common. The aim of steroid therapy 
is to control the intense inflammatory reaction and 
cytokine storm, so as to improve clinical outcomes. 
In most cases however, details of the dosage and 
duration of therapy were not reported. Overall survival 
rates in those who received such adjunctive steroid 
therapy and those who did not were 57% (12/21) 
and 83% (10/12), respectively. However, given the 
limited number of case reports, and the differences 
in the choice, dosage and duration of steroid therapy, 
recommendations cannot be made based on the 
available comparisons. Further controlled studies 
appear necessary before making a recommendation 
on their optimal use, if any. Other immunotherapies 
(intravenous immunoglobulin, chemotherapy 
with etoposide or vincristine, splenectomy, plasma 
exchange, and epipodophyllotoxin) have also met 
with variable success. As the number of patients with 
tuberculosis-associated HLH was limited, the role of 
such immunotherapeutic agents remains unclear.
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